Truist Securities raises BioNTech stock price target on new partnership

Truist Securities raised its BioNTech (BNTX) price target to $155 from $151, maintaining a Buy rating, following BioNTech's agreement with Bristol Myers Squibb to develop and commercialize BNT327. The partnership is viewed favorably due to shared R&D expenses and leveraging Bristol Myers Squibb's expertise in immuno-oncology. Other analysts have also adjusted their outlook, with Clear Street raising its target to $181 and Goldman Sachs initiating coverage with a Neutral rating and a $110 price target, reflecting varied perspectives on BioNTech's financial position and market uncertainties.

Analysis

BioNTech (BNTX) has received a moderately positive reassessment from analysts, primarily driven by its strategic partnership with Bristol Myers Squibb (BMY) for the joint development and commercialization of BNT327, an immuno-oncology candidate. Truist Securities raised its price target to $155 from $151, maintaining a Buy rating, citing the deal's benefits in sharing R&D expenses and leveraging BMY's expertise. This collaboration includes $3.5 billion in upfront and near-term cash for BioNTech, potential milestone payments of $7.6 billion, and a 50% profit share, underscoring BioNTech's strong financial position, further evidenced by a current ratio of 10.18. However, analyst sentiment is not universally bullish. H.C. Wainwright lowered its target to $134, despite a Buy rating, following first-quarter 2025 net earnings per share of €1.73 which missed estimates, though revenue of €244.4 million surpassed forecasts. Conversely, Clear Street analysts increased their target to $181, optimistic about oncology developments. Goldman Sachs initiated coverage with a Neutral rating and a $110 target, acknowledging solid financials but highlighting vaccine market uncertainties. UBS also holds a Neutral rating with a $115 target, referencing a Phase 3 trial with positive yet not statistically significant overall survival data. The U.S. FDA's plans for new COVID-19 booster trials add another layer to BioNTech's operational landscape, reflecting a dynamic environment with both significant opportunities in oncology and ongoing challenges in the vaccine sector.

Key Decisions for Investors

• Investors should closely monitor the execution and clinical progress of the BNT327 program partnered with Bristol Myers Squibb, as its success is pivotal to realizing the upside reflected in more bullish analyst targets.
• Given the mixed first-quarter 2025 earnings results and varied clinical trial interpretations, pay close attention to upcoming financial disclosures and clinical data readouts to assess the company's ability to translate its pipeline into consistent financial performance.
• Consider the wide dispersion in analyst price targets (ranging from $83.36 to $181) and ratings as indicative of both the high-reward potential in BioNTech's oncology pipeline and the persistent risks associated with the evolving COVID-19 vaccine market and regulatory landscape.